Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 10:31:03 2024-06-28 EDT			5-day change	1st Jan Change
273.8 ^USD	+0.66%		-4.92%	-15.20%

06-24	RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating	MT
06-24	OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.	CI

OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.

June 23, 2024

OncoCyte Corporation announced a private placement that it will receive funding of $3,500,000 on June 24, 2024. The transaction will include participation from returning investor, Bio-Rad Laboratories, Inc.

Latest news about Bio-Rad Laboratories, Inc.

RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating	06-24	MT
OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.	06-23	CI
Transcript : Bio-Rad Laboratories, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 10:30 AM	06-06
Bio-Rad Laboratories, Inc. Appoints Anette Engelhardt as Executive Vice President and President of Clinical Diagnostics Group, Effective June 10, 2024	05-30	CI
Transcript : Bio-Rad Laboratories, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:05 PM	05-14
UBS Adjusts Price Target on Bio-Rad Laboratories to $385 From $420, Maintains Buy Rating	05-08	MT
RBC Adjusts Price Target on Bio-Rad Laboratories to $414 From $420	05-08	MT
Citigroup Adjusts Price Target on Bio-Rad Laboratories to $300 From $365	05-08	MT
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip	05-07	RE
Bio-Rad Laboratories Q1 Non-GAAP Earnings, Revenue Decline	05-07	MT
Transcript : Bio-Rad Laboratories, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 Revenue $610.8M, vs. Street Est of $620.1M	05-07	MT
Earnings Flash (BIO) BIO-RAD LABORATORIES Reports Q1 EPS $2.29, vs. Street Est of $2.14	05-07	MT
Bio-Rad Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on July 20, 2023.	05-06	CI
RBC Capital Adjusts Price Target on Bio-Rad Laboratories to $420 From $474	04-29	MT
Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group	04-26	CI
Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322	04-15	MT
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	04-11	CI
Bio-Rad Laboratories COO Andrew Last to Retire in September	04-10	MT
Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire	04-10	CI
RBC Trims Price Target on Bio-Rad Laboratories to $474 From $480, Keeps Outperform Rating	04-08	MT
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $365 From $400	04-03	MT
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center	03-25	MT

Chart Bio-Rad Laboratories, Inc.

Duration

Period

More charts

Company Profile

Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Bio-Rad Laboratories, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

272 USD

Average target price

366.4 USD

Spread / Average Target

+34.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIO-RAD LABORATORIES, INC.	-15.20%	7.82B
ABBOTT LABORATORIES	-5.31%	182B
MEDTRONIC PLC	-4.42%	102B
BECTON, DICKINSON AND COMPANY	-4.75%	66.74B
DEXCOM, INC.	-8.09%	45.55B
CENCORA, INC.	+10.31%	44.89B
HOYA CORPORATION	+6.13%	40.62B
METTLER-TOLEDO INTERNATIONAL, INC.	+17.51%	30.04B
TERUMO CORPORATION	+14.80%	24.34B
WEST PHARMACEUTICAL SERVICES, INC.	-5.58%	23.95B

Other Medical Equipment, Supplies & Distribution